Selective D-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis: A Randomized Trial  by Linkins, L.A. et al.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 5 Abstracts 1449interval, 2.71-2.81) compared with never smokers. This was despite the fact
that 44% of the baseline smokers who responded to the 8-year resurvey had
stopped smoking at that point. Mortality was tripled, largely irrespective of
age, in those still smoking at the 3-year resurvey (rate ratio, 2.97; 2.88-
3.07). The 12-year mortality was doubled (rate ratio, 1.98; 1.91-2.04)
even for women smoking fewer than 10 cigarettes daily at baseline. Of
the 30 most common causes of death, 23 were increased signiﬁcantly in
smokers. Excess mortality was mainly from diseases caused by smoking.
Among ex-smokers who stopped permanently at ages 25 to 34 or at ages
35 to 44 years, the respective relative risks were 1.05 (95% conﬁdence
interval, 1.00-1.11) and 1.20 (1.14-1.26) for all-cause mortality and 1.84
(1.45-2.34) and 3.34 (2.76-4.03) for lung cancer mortality.
Comment: Please see also the report by Jha P et al providing similar
data from the United States, also featured in this Abstract Section of the
Journal. The data are remarkably similar between the two countries. In
particular, it is important to note that although some excess mortality
remains among long-term ex-smokers, it is only about 3% and 10% of excess
mortality among continued smokers. If the data in this study were
combined with the 2010 U.K. national death rates, it would indicate 53%
of smokers and 22% of never smokers die before age 80 years with an 11-
year life-span difference in favor of the never smokers.Aortic Pathology Determines Midterm Outcome After Endovascular
Repair of the Thoracic Aorta. Report from the Medtronic Thoracic
Endovascular Registry (MOTHER) Database
Patterson B, Holt P, Nienaber C, et al. Circulation 2013;127:24-32.
Conclusion: Midterm outcomes of endovascular repair of the
thoracic aorta (TEVAR) are determined by presenting pathology, mode
of hospital admission, and associated comorbidities.
Summary: For endovascular repair of the abdominal aorta, the early
mortality advantage is lost after 2 to 3 years as a result of late aortic rupture
(Greenhalgh RM et al, N Engl J Med 2010;362:1863-71). The authors
indicate there is concern that a similar “catch-up” phenomenon may also
affect TEVAR. The thoracic aorta has many different pathologies. To
help determine whether TEVAR offers a durable solution to prevent
aortic-related death, it seems reasonable to examine whether outcome of
TEVAR is pathology-speciﬁc. The authors in this report built a database
from ﬁve prospective studies and a single-institutional series. Perioperative
adverse events were calculated as well as midterm death and reintervention
rates for TEVAR. Multivariable analysis, logistical regression modeling, and
Kaplan-Meier survival curves were used. There were 1110 patients in the
database. Of these, 670 had thoracic aortic aneurysm, 195 had chronic
type B dissection, and 114 had acute type B aortic dissection. Elective
mortality was 3% in patients with chronic dissection and 5% in patients
with aneurysm. Multivariate analysis indicated age, mode of admission,
American Society of Anesthesiologists grade, and pathology were indepen-
dent predictors of 30-day death (P < .05). All-cause mortality was 8, 4.9,
and 3.2 deaths per 100 patient-years for thoracic aortic aneurysm, acute
type B dissection, and chronic type B dissection, respectively. Rates of
aortic-related death were 0.6, 1.2, and 0.4 deaths per 100 patient-years
for thoracic aortic aneurysm, acute type B aortic dissection, and chronic
type B aortic dissection, respectively. Freedom from aortic reintervention
at 6 years was 84% in the thoracic aortic aneurysm group, 71% in the chronic
type B aortic dissection group, and 46% in the acute type B aortic dissection
group. The most common cause for reintervention in the thoracic aortic
aneurysm group was endoleak (most commonly type 1,) and malperfusion
was the most common reason for reintervention in both dissection groups.
Comment: The data indicate that in patients with thoracic aortic
aneurysm, midterm non-aortic-related mortality is high. TEVAR appears,however, to offer excellent protection in the midterm from aortic-related
mortality in patients with thoracic aortic aneurysm and type B dissections.
Protection is dependent on high rates of aortic reintervention.Selective D-Dimer Testing for Diagnosis of a First Suspected Episode
of Deep Venous Thrombosis: A Randomized Trial
Linkins LA, Bates SM, Lang E, et al. Ann Intern Med 2013;158:93-100.
Conclusion: For patients with a ﬁrst episode of suspected deep vein
thrombosis (DVT), selected D-dimer testing is more efﬁcient than having
everyone undergo D-dimer testing.
Summary: D-dimer is a sensitive but not a speciﬁc test for the diag-
nosis of DVT. In effect, this means that a negative result (D-dimer level
<0.5 mg/mL) excludes the diagnosis of DVT but a positive result ($0.5
mg/mL) indicates additional testing, generally venous ultrasound imaging,
is required. The authors postulate that it may be possible to improve the
tradeoff between D-dimer sensitivity and speciﬁcity by varying the
threshold distinguishing a negative from positive test result on the basis
of the patient’s clinical probability of having DVT. They further postulate
that because the prevalence of DVT is low in patients with low clinical
pretest probability (C-PTP), use of a higher, less sensitive threshold could
exclude DVT in more patients without signiﬁcantly increasing the number
of missed diagnoses. The authors therefore designed this study to deter-
mine whether using a selective D-dimer testing strategy based on
C-PTP for DVT is safe and potentially reduces diagnostic testing
compared with use of a single D-dimer threshold for all patients. This
was a randomized multicentered controlled trial that took place in ﬁve
Canadian hospitals. Patients were allocated using a central automated
system. Study adjudicators and ultrasonographers, but not other study
personnel, were blinded to patient allocation. The study included consec-
utive patients with a ﬁrst episode of suspected DVT. There were two basic
trial groups. Those with selected testing (n ¼ 860) were deﬁned as having
D-dimer testing for outpatients with low or moderate C-PTP (DVT was
excluded at D-dimer levels <1.0 mg/mL [low C-PTP] or with a D-dimer
level <0.5 mg/mL with moderate C-PTP). Venous ultrasonography
without In the non-selected testing group D-dimer testing was performed
for outpatients with high C-PTP and for in-patients, or for those assigned
uniform testing (n ¼ 863), deﬁned as D-dimer testing for all participants
(DVT excluded at D-dimer levels <0.5 mg/mL). The primary study end
point was the proportion of patients not diagnosed with DVT during
initial testing who had an episode of symptomatic venous thromboembo-
lism (VTE) during 3 months of follow-up and the proportion of patients
undergoing D-dimer testing and ultrasound imaging. The incidence of
new symptomatic VTE at 3 months in those initially judged negative for
DVT was 0.5% in both study groups (difference, 0.0 percentage points;
95% conﬁdence interval [CI] 0.8 to 0.8 percentage points). In the
selected testing group, the proportion of patients who required D-dimer
testing was reduced by 21.8% (95% CI, 19.1%-24.8%). Selective testing
reduced the proportion that required ultrasonography by 7.6% (95% CI,
2.9%-12.2%) overall, and by 21.0% (95% CI, 14.2%-27.6%) in outpatients
with low C-PTP.
Comment: In essence, the trial indicates that a selective strategy using
a higher D-dimer threshold to exclude a ﬁrst acute DVT in outpatients with
a low clinical pretest probability of VTE and in outpatients with high clinical
pretest probability and in all inpatients is safe and more effective than
uniform testing with D-dimer. This study, however, resulted only in
a 7.7% overall decrease in the use of ultrasound imaging. Therefore, from
the view of those who run vascular laboratories, the strategy advocated
here is not likely to have a major impact on the selection of patients with
possible DVT for ultrasound assessment.
